Research News

Genetic Counseling and Testing by Oncologists Feasible for Ovarian Cancer Patients

(April 3, 2018) A study in the Journal of Clinical Oncology explored the effects of oncologists, rather than genetic counselors, testing ovarian cancer patients for BRCA mutations…

Read on

Discovery of New Gene Mutation That Increases Ovarian Cancer Risk, Passed Down Through Paternal Lineage

(February 22, 2018) Researchers at Roswell Park Comprehensive Cancer Center, including Kunle Odunsi, MD, PhD, senior author of the study and current OCRFA Scientific Advisory Committee member, have discovered a mutation of an unidentified gene that…

Read on

US Preventive Services Task Force: Ovarian Cancer Screening Not Effective for Low-Risk Women

(February 14, 2018) Today the US Preventive Task Force updated their recommendation on ovarian cancer screening, reaffirming their 2012 position that screening average risk women for ovarian cancer is not effective in reducing mortality from the…

Read on

Ovarian Cancer Risk and BRCA1 Methylation

(January 31, 2018) A study published in the Annals of Internal Medicine explains that researchers now believe that the methylation of normal BRCA1 gene promotion, not solely BRCA1 mutation, is a risk factor for ovarian cancer…

Read on

HIPEC Beneficial in Late Stage Ovarian Cancer

(January 29, 2018) A study recently published in the New England Journal of Medicine looked at the difference between two treatment strategies for newly diagnosed stage III epithelial ovarian cancer patients, with the goal of identifying the…

Read on

Can Cancer Be Detected and Located by a Blood Test?

(January 25, 2018) CancerSEEK is a blood test designed to detect cancer by analyzing levels of proteins and mutations in cell-free DNA…

Read on

OCRFA Awards $5.3 Million in Scientific Research Grants for 2018

(January 25, 2018) OCRFA has just awarded more than $5.3 million in new scientific research grants for ovarian cancer, bringing our total investment in life-saving research to over $80 million…

Read on

OCRFA Research Shows Novel Combination Therapy Effective in Ovarian Cancer

(December 20, 2017) Cell Reports published new research from the Wistar Institute, which looked at the potential benefits of a therapy that combines PARP inhibitors and BET inhibitors for ovarian cancer patients without BRCA mutations…

Read on

The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer

(December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian…

Read on

Study Reveals Overall Survival Disparities Among Race and Stage

(December 8, 2017) The results of the CONCORD-2 study, recently published in Cancer, show a large difference in ovarian cancer survival between black women and white women, and also between stages at diagnosis…

Read on

Phase II Trial Points to Possible Benefits of IP Chemotherapy after Neoadjuvant Therapy and Surgery

(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology…

Read on

OCRFA Funded Research Identifies Mechanism Underlying Ovarian Cancer Development

(November 22, 2017) A recent paper published in the Journal of Clinical Investigation reports that a subset of ovarian cancers reduce the expression of a critical gene involved in recycling the cells’ proteins, known as ubiquitin B (UBB)…

Read on